I-Mab expected to post a loss of 48  cents a share - Earnings Preview

NovaBridge Biosciences

25/03/2022 14:25

* I-Mab  IMAB.OQ   IMAB.O  is expected to report results on
March
29.
    * ​Refinitiv's mean analyst estimate for I-Mab is for a loss
of 48
cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 16 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for I-Mab is
$96​,
above​ its last closing price of $20.00. ​​​

This summary was machine generated March 25 at 14:25 GMT.  All
figures in US dollars  unless otherwise stated